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In dogs and cats proteinuria is a negative prognostic for chronic kidney disease and is 
associated with degree of functional impairment as well as the risk of a uremic crisis, 
progressive worsening of azotemia or death.  
 
Normal dogs and most normal cats should have a urine protein:creatinine ratio that is <0.4 
and <0.2, respectively; persistent proteinuria above this magnitude warrants attention. 
 
Administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor 
blockers is considered a standard of care in dogs and cats with renal proteinuria where the 
UPC is >0.5-1 and >0.2-0.4 respectively. 
 
Blood pressure control and nutritional modification are also important considerations and 
part of the standard of care for dogs and cats with renal proteinuria.  
 
Renal biopsy and administration of immunosuppressive agents should be considered in 
dogs with glomerular proteinuria that have not responded to standard therapy. 
  
SYNOPSIS 
Proteinuria is a negative prognostic indicator for dogs and cats with for chronic kidney 
disease and is associated with degree of functional impairment as well as the risk of a 
uremic crisis or death. The normal kidney is so highly efficient at preventing passage of 
proteins into the filtrate and reabsorbing the proteins that do get through that a normal 
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dog or cat should excrete very little protein and have a urine protein:creatinine ratio that is 
<0.4 or <0.2, respectively; persistent proteinuria above this magnitude warrants attention. 
Administration of angiotensin converting enzyme inhibitors (e.g., benazepril, enalapril) 
and/or angiotensin receptor blockers (e.g., telmisartan), blood pressure control and 
nutritional modification are considered a standard of care in dogs and cats with renal 
proteinuria. Renal biopsy and administration of immunosuppressive agents should be 
considered in dogs with glomerular proteinuria that have not responded to standard 
therapy; glomerular proteinuria is uncommon in cats. Targeted patient monitoring is 
essential when instituting management of renal proteinuria. 
 
Proteinuria as a Prognostic Indicator in Chronic Kidney Disease 
 Proteinuria is a negative prognostic indicator for both dogs and cats with chronic 
kidney disease. In dogs with chronic kidney disease, an initial urine protein: creatinine 
ratio (UPC) of >1.0 was associated with a threefold greater risk of developing a uremic 
crisis and death (Jacob et al, 2005). The relative risk of adverse outcomes increased 1.5 
times for every increase in the UPC by 1. In another canine study, proteinuria correlated 
with the degree of functional impairment, as measured by glomerular filtration rate; dogs 
with UPC of <1.0 lived 2.7 times longer on average than dogs with a UPC >1.0 (Wehner et al, 
2008).  
When nonazotemic cats were prospectively and longitudinally evaluated, 
proteinuria was found to be significantly associated with the development of azotemia by 
12 months (Jepson et al, 2009). Both proteinuria and serum creatinine were related to 
shortened survival in cats with chronic kidney disease (Syme et al, 2006; King et al, 2007). 
 5 
This was true even when cats had UPC as low as 0.2-0.4. 
Chronic proteinuria has been shown to be associated with interstitial fibrosis as 
well as tubular degeneration and atrophy, although the exact mechanisms of injury are a 
subject of debate (Toblli et al, 2012; Pollock et al, 2007). There is some evidence that 
reabsorbed proteins and lipids are directly toxic to the tubular epithelial cells, triggering 
inflammation and apoptosis. In addition, excessive lysosomal processing of proteins leads 
to lysosomal rupture and the intracellular release of cytotoxic enzymes. Proteinuria may 
increase the workload of the tubular epithelial cell beyond its capabilities. Proteinacious 
casts cause tubular obstruction, which further injures the cells. Glomerular injury results 
decreased perfusion of the tubulointerstitium, resulting in cellular hypoxia. Increased 
glomerular permselectivity increases the filtration of other substances, such as transferrin, 
that cause additional tubular injury.   
Because proteinuria is associated with negative outcomes it is imperative that the 
practice veterinarian has a thorough understanding of appropriate assessment and 
management of proteinuria in dogs and cats with chronic kidney disease. 
 
Normal Renal Handling of Protein  
The glomerulus is a complex structure that functions as a filter, across which an 
ultrafiltrate of the plasma is formed. This filtration system, made up by the fenestrated 
endothelium, glomerular basement membrane and visceral epithelial cells (podocytes) is 
freely permeable to water and small dissolved solutes, but retains cells and most 
macromolecules, such as proteins. The podocyte is the most differentiated cell in the 
glomerulus and essential to the filtration unit (Tobilli et al, 2012). In addition to these 
 6 
factors, glycocalyx has been found to play an important role in maintaining glomerular 
permselectivity by restricting the passage of proteins (Singh et al, 2007). The major 
determinant of passage into the filtrate is molecular size. Low-molecular weight proteins, 
such as insulin and immunoglobulin fragments, pass freely through the filter, but as 
molecules increase in size they are retained with increasing efficiency. Only small amounts 
of substances larger than 60,000 to 70,000 daltons pass in to the filtrate. The podocyte foot 
processes, epithelial slits, basement membrane and endothelium are all rich in negatively 
charged glycoproteins that create an ionic charge barrier and impede the passage of 
negatively charged molecules more than would be expected based on their size alone. 
Albumin, a negatively charged protein with a molecular weight of 69,000 daltons, is 
normally largely excluded from the filtrate. Despite this complex filtration system, the 
glomerulus normally leaks albumin. Rapid endocytosis and hydrolysis of these proteins by 
proximal tubular cells occurs. Filtered albumin and other proteins are ultimately released 
to the blood as amino acids. A normal animal should excrete virtually no protein in the 
urine, but certainly an amount that is below the limit of detection of routine urine protein 
assays (Maack, 2011).  
 
Laboratory Tests for Urine Protein 
The urine dipstick, the sulfosalicylic turbidimetric test (SSA, bumin test) or the UPC 
can be used to measure total urine protein. The urine dipstick is the most readily available 
test of urine protein but is also the least reliable. Both false positives and false negatives 
occur. The sensitivity and specificity of the urine protein dipstick are as low as 54% and 
69%, respectively, in the dog and 60% and 31%, respectively, in the cat. While the urine 
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dipstick primarily detects albumin, it also measures globulins. The SSA is more reliable 
than the urine dipstick for the detection of proteinuria (both albumin and globulin); 
however, use of this test requires either having the appropriate reagents and standards on 
hand or sending the urine sample to a reference lab. The amount of protein that is present 
in the urine of normal dogs and cats is below the lower limit of detection for both of these 
tests. When both urine dipstick and SSA test results are available, the results of the SSA test 
should be given greater consideration than those of the urine dipstick. Positive results with 
either of these tests must be interpreted in light of the urine specific gravity.  
Dogs and cats with repeat positive dipstick or SSA results in urine sample that is 
free of pyuria or a color change from hematuria should have urine protein losses quantified 
by the UPC. The UPC is determined using a quantitative test for total urine protein, the 
results of which are expressed as a ratio to urine creatinine thereby eliminating the need to 
consider the urine specific gravity when interpreting the results. The ratio correlates well 
with 24-hour urine protein losses and can be measured either in-house or as a send out 
test. Normal dogs, female cats and neutered male cats should have a UPC that is <0.2 (Table 
1). Normal intact male cats can have UPC up to 0.6, most likely due to the excretion of large 
amounts of cauxin.  
Persistent microalbuminuria is the mildest, and often earliest, detectable form of 
proteinuria. Urine albumin can be measured quantitatively through a commercial reference 
laboratory using a specifies-specific assay. The urine is diluted to a standard concentration 
(1.010) prior to assay, eliminating the need to consider urine specific gravity when 
interpreting the test results. Alternatively, some labs report urine albumin as a ratio to 
creatinine (i.e., mg albumin/g creatinine). Microalbuminuria is defined as concentrations of 
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albumin in the urine that are greater than normal but below the limit of detection using the 
urine dipstick. By this definition, the upper end of urine albumin concentrations that are 
still considered to be microalbuminuria is 30 mg/dl (or 300 mg albumin/g creatinine). 
Urine albumin concentrations above this are called overt albuminuria. Proteinuria of this 
magnitude can often be detected using the UPC.  
 
Clinical Assessment of Proteinuria 
Accurate assessment of proteinuria involves 3 key elements:  persistence, 
localization, and magnitude (Lees et al, 2005).  Persistent proteinuria is defined as 
proteinuria that has been detected on 3 or more occasions, 2 or more weeks apart. 
Persistent proteinuria should be localized as being pre-renal, post-renal, or renal (Table 2). 
Identifying the cause of proteinuria in an affected dog or cat is important so that 
appropriate therapeutic measures can be implemented. Renal proteinuria that is 
glomerular or tubulointerstitial in origin is the most relevant form of proteinuria when 
managing dogs with chronic kidney disease. However, it is important to ensure that 
proteinuria is not due to pre-renal or post-renal causes because the management of these 
disorders varies substantially from the management of chronic kidney disease. Functional 
proteinuria is not very common in dogs and cats, or at least poorly documented.  
Once pre-renal and post-renal causes of persistent proteinuria are eliminated, 
magnitude is used to help determine if renal proteinuria is glomerular or tubulointerstitial 
in origin. Magnitude is assessed using a quantitative test for urine protein (generally UPC 
but could also be urine albumin). Once pre-renal and post-renal causes of proteinuria have 
been excluded, it is recommended that a UPC be evaluated in all dog and cats with 
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persistent proteinuria as determined by dipstick or SSA.  
The International Renal Interest Society (IRIS) has recommended substaging dogs 
and cats with chronic kidney disease on the basis of their UPC (Table 1). Dogs that have 
renal proteinuria and a UPC ≥2.0 usually have glomerular disease, whereas dogs with UPC 
<2.0 might have either glomerular disease or tubulointerstitial disease. Glomerular 
diseases occur much less commonly in cats but should be suspected when the UPC is ≥2. 
Concurrent hypoalbuminuria is added evidence that glomerular disease is present.  
Urine sodium-dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) can 
be used to help determine if renal proteinuria is glomerular or tubulointerstitial in origin 
(Nabity 2010). Finding predominantly low molecular weight proteins is consistent with 
tubulointerstitial disease whereas glomerular damage is more likely associated with a 
pattern of intermediate and high molecular weight proteins. When there is concurrent 
glomerular and tubulointerstitial disease, a mixture of sizes is expected. In addition to SDS-
PAGE, there are certain novel biomarkers that may prove in the future to identify 
tubulointerstitial damage is present (e.g., retinol binding protein, kidney injury molecule-
1).   
 
Inhibition of RAAS to Manage Proteinuria 
Hemodynamic forces influence the transglomerular movement of proteins and it 
follows that altering renal hemodynamics would be effective in reducing proteinuria 
(Brown et al, 2013).  The renin-angiotensin-aldosterone system (RAAS) has been the major 
target system for this approach to reducing proteinuria (Figure 1). Agents that target RAAS 
include the angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers 
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(ARB), and aldosterone receptor antagonists (Table 3). Although renin inhibitors are being 
used in people, they have not been used to any great extent in dogs and cats. All RAAS 
inhibitors have antihypertensive effects although most of them only minimally reduce 
blood pressure (i.e., 10-15%). These drugs likely reduce proteinuria by several 
mechanisms in addition to the expected decrease in glomerular capillary hypertension. 
Likewise, the reduction in proteinuria is greater than would be expected on the basis of 
their antihypertensive effects alone. RAAS inhibition is considered a standard of care in 
dogs and cats with renal proteinuria where the UPC is >0.5-1 and >0.2-0.4 respectively. The 
inhibitors of RAAS reduce proteinuria in populations of animals but the effect in individual 
animals might vary. It may take trial and error with different drugs or combinations of 
drugs before the target antiproteinuric effect is achieved (see Monitoring Drug Therapy 
below); some animals may never achieve target reductions.  
Angiotensin Converting Enzyme Inhibitors  
ACEi administration has been associated positive outcomes in dogs, cats and people 
with chronic kidney disease (Grauer et al, 2015; Tenhundfeld et al, 2009; King et al, 2006; 
Mizutani et al, 2006). Enalapril significantly reduced proteinuria and delayed the onset or 
the progression of azotemia in dogs with glomerulonephritis (Grauer et al, 2015). In dogs 
with partial nephrectomies, enalapril treated dogs had a reduction in glomerular and 
tubulointerstitial lesions following 6 months of treatment (Brown et al, 2003). Likewise, 
dogs with chronic kidney disease that were given benazepril had higher glomerular 
filtration rates and lower UPCs when compared to a placebo-treated group (Tenhundfeld et 
al, 2009). 
In cats, benazepril administration was associated with reduced glomerular capillary 
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pressure in cats with induced chronic kidney disease (Brown et al, 2001). In cats with 
naturally occurring chronic kidney disease, benazepril was associated with a reduction in 
proteinuria, even in the subgroup of cats with initial UPC of <0.2; cats with initial UPC >1 
demonstrated better appetites when given benazepril vs placebo. Although these drugs 
reduce proteinuria in cats, studies have not yet demonstrated a positive event on survival 
or progression of chronic kidney disease. 
Proposed mechanisms for these effects include decreased efferent glomerular 
arteriolar resistance leading to decreased or normalized glomerular transcapillary 
hydraulic pressure, reduced loss of glomerular heparan sulfate, decreased size of the 
glomerular capillary endothelial pores, improved lipoprotein metabolism, slowed 
glomerular mesangial growth and proliferation, and inhibition of bradykinin degradation.  
Initially an ACEi is given once daily, but more than half of the dogs will need twice 
daily administration eventually and perhaps additional dosage escalations (Figure 2) 
(Grauer et al, 2000). Many veterinarians are concerned about administering an ACEi to a 
dog or cat that is already azotemic. In people, the renoprotective effects of ACEi are 
independent of the baseline renal function and ACEi slowed progressive disease even in 
patients with severe renal failure (Ryan and Tuttle, 2008). In reality, it seems to be 
uncommon for dogs and cats to have severe worsening of azotemia (i.e., >30% increase 
from baseline) due to ACEi administration alone provided animals are clinically stable 
prior to the introduction of these agents. Dogs that are dehydrated may be at highest risk 
for worsening of azotemia after initiating ACEi therapy; euvolemia should be achieved 
before initiating an ACEi to these patients. Furthermore, some caution is warranted when 
administering an ACEi to a dog or cat in late stage 3 or stage 4 CKD (e.g., low initial starting 
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dose with small incremental increases).   
Many veterinarians wonder if one drug is better than another in animals with 
reduced renal function. The pharmacokinetics of ACEi are complicated and the effects of 
disease on the pharmacodynamics of these drugs in not necessarily predictable. There is no 
scientific basis to support that one ACEi has superior pharmacodynamic action. Benazepril 
and its active metabolite, benazeprilat, are largely eliminated by the biliary route with a 
smaller fraction being excreted in the urine; impaired renal function does not affect the 
clearance of this drug in dogs (Lefebvre et al, 1999). On the other hand, enalapril and its 
active metabolite, enalaprilat, are primarily eliminated by the kidney.  Animals in IRIS late 
stage 3 or stage 4 CKD may require a lower dosage of enalapril to achieve target 
antiproteinuric effects.  
Angiotensin Receptor Blockers  
ARBs block the angiotensin II type 1 receptor. Several ARBs have been studied 
extensively in people with glomerular disease and lead to a reduction in proteinuria similar 
to that which is seen with ACEi. People treated with losartan had an average reduction in 
proteinuria of 35% from baseline during a 3.4 year follow up period; much of this 
reduction was in the first 6 months of therapy (Bakris et al, 2008). In irbesartan treated 
patients, every 50% reduction in proteinuria during the first 12 months of therapy reduced 
the risk of a negative renal outcome by more than half (Bakris et al, 2008).  
The use of ARBs in dogs and cats with proteinuric chronic kidney disease is still 
being developed. The one that seems to be the most effective is telmisartan; however, 
losartan has been used more extensively (Sent et al, 2015; Bugbee et al, 2014). Even though 
dogs do not appear to produce one of the major active metabolites of losartan, there is good 
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evidence that losartan exerts pharmacodynamic effects in dogs (Christ et al, 1992). 
Contrary to this, pharmacodynamic studies suggest that losartan may not be effective in 
cats, at least in attenuation of pressor responses (Jenkins et al, 2015).   
Telmisartan is more lipophilic, and has a longer half-life than losartan; its blocking 
effects persist for longer than would be predicted from its plasma half-life. Furthermore, it 
has a higher affinity for, and dissociates more slowly from, the angiotensin-1 receptor. 
Therefore, it is not surprising that telmisartan was shown to be more effective in reducing 
proteinuria in people with diabetic nephropathy (Bakris et al, 2008) Telmisartan was as 
effective as amlodipine in controlling blood pressure in people with chronic kidney disease 
(Nakamura et al, 2007). Similarly telmisartan attenuated angiotensin I-induced blood 
pressure response to a greater degree than did benazepril in normal cats (Jenkins et al, 
2015). If this is true in dogs and cats, telmisartan might be the initial RAAS inhibitor of 
choice when proteinuria and systemic hypertension are both present. A randomized 
controlled clinical trial comparing the effects of telmisartan and benazepril on proteinuria 
in cats with naturally occurring CKD demonstrated overall, telmisartan was as effective as 
benazepril in preventing an increase in UPC occurring over a 6-month treatment period. 
Indeed, telmisartan reduced UPC relative to the pre-treatment value at all time points 
evaluated in the 6-month trial whereas benazepril only reduced UPC at very early time 
points (Sent et al, 2015). 
Combined Therapy with ACEi and ARB  
There may be an added benefit to combined administration of an ACEi and an ARB 
because of the inability of either class of drug to provide complete RAAS blockade when 
given alone (Bakris et al, 2008). Although not evaluated in dogs and cats, studies in people 
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have suggested that these drugs may be additive or perhaps even synergistic in reducing 
proteinuria (Linas 2008). The dosage of each individual drug might be reduced during 
combined therapy, thereby reducing the likelihood of adverse effects. However, the 
approach of combining these two agents must be used cautiously in light of a human study 
where elderly patients prescribed this combination had a higher risk of kidney failure and 
death (McAlister et al 2011).  Controlled studies are needed in dogs to determine if the 
antiprotienuric effects of ACEi and ARBs are optimized by combination therapy or 
monotherapy with individualized dosage escalation.   
Aldosterone Breakthrough  
Complete blockade of the RAAS system is generally not achieved with RAAS 
inhibitors. In the absence of angiotensin converting enzyme, angiotensin II is produced by 
other kinases and is therefore, not completely suppressed by an ACEi alone. Blockade of the 
angiotensin II type 1 receptor with an ARB, may give rise to a compensatory increase in 
renin activity, and therefore and incomplete block of the RAAS (Laverman et al, 2002). 
Combination therapy increases the degree of blockade, but it is still may not be more than 
75-80% complete.  
Serum aldosterone increases over time in some people treated even with maximal 
dosages of RAAS inhibitors, a phenomenon referred to as aldosterone breakthrough. The 
incidence of aldosterone breakthrough in people treated with RAAS inhibitors for chronic 
kidney disease, systemic hypertension or heart failure is between 10 and 53% (Bomback 
and Klemmer 2007). Prolonged hyperaldosteronism can have adverse effects on the heart, 
systemic blood vessels and glomeruli. Therefore, it is not surprising that some people that 
experience aldosterone breakthrough during treatment for various glomerular diseases 
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have more negative outcomes (e.g., higher magnitude proteinuria, greater reduction in 
glomerular filtration rate) (Horita et al, 2006; Schjoedt et al, 2004). Preliminary studies 
have demonstrated that aldosterone breakthrough may occur in up to one-third of dogs 
with proteinuric renal diseases that are receiving RAAS inhibitors (Ames, unpublished 
data). More study is needed to determine if aldosterone breakthrough is associated with 
poorer treatment outcomes in dogs.  
Aldosterone Receptor Antagonists 
Aldosterone-receptor antagonists have been shown to reduce proteinuria and 
stabilize kidney function in an additive fashion to ACEi and/or ARB in people, particularly if 
they have evidence of aldosterone breakthrough before adding the aldosterone-receptor 
antagonist (Bianchi et al, 2006).  Eplerenone may be the drug of choice in people because 
the relative lack of binding to androgen and progesterone receptors produces fewer 
endocrine side effects.  However, endocrine side effects of spironolactone in dogs are less 
problematic and the preference is unclear in veterinary medicine. Although spironolactone 
has been used most commonly in veterinary medicine, there is little evidence supporting 
the efficacy of this drug in dogs in the management of glomerular disease. Sprionoloactone 
should only be effective if serum or urine aldosterone concentrations are increased, 
indicative of aldosterone breakthrough.  This drug could be tried in dogs that have high 
serum or urine aldosterone concentrations and persistent proteinuria in spite of treatment 
with an ACEi and/or ARB. The drug should not be used in cats until more is known about 
its efficacy and safety in this species.  
Monitoring Drug Therapy 
The UPC, urinalysis, systemic blood pressure and serum albumin, creatinine and 
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potassium concentrations (in fasting samples) should be monitored at least quarterly in all 
animals being treated for proteinuric renal disease. However, those that are having new 
drugs introduced or dosage modifications being made for drugs already being 
administered should be monitored more frequently (Figure 2). One to 2 weeks after an 
ACEi or ARB is added or changed, the UPC, serum creatinine, serum potassium and 
systemic blood pressure should be evaluated to verify that the recent change in therapy has 
not resulted in a severe worsening of renal function (i.e., >30% increase in serum 
creatinine), a concerning increase in serum potassium concentrations, or hypotension (an 
unlikely occurrence with these drugs).   
Day-to-day variations in the UPC occur in most dogs with glomerular proteinuria, 
with greater variation occurring in dogs with UPC >4 (Nabity et al, 2007); variations also 
occur in cats but these have not been as well characterized. Changes in urine protein 
content are most accurately measured by assessing trends in the UPC over time.  Because 
there is greater day-to-day variation in dogs with UPC >4, consideration should be given to 
either averaging 2-3 serial UPC or measuring a UPC in urine that has been pooled from 2-3 
collections (LeVine et al, 2010). In one study, demonstration of a significant difference 
between serial values in proteinuric dogs required a change by at least 35% at high UPC 
values (near 12) and 80% at low UPC values (near 0.5) (Nabity et al, 2007). Thus a 
reduction in UPC near these reported magnitudes without an increase in the serum 
creatinine concentration is required to indicate improvement or response to therapy. 
Making Therapeutic Adjustments for RAAS Inhibitors 
An ACEi is the initial therapy in most dogs and cats with proteinuria, with the typical 
starting dosage of 0.5 mg/kg q24h (Figure 2). However, the ARB telmisartan may soon 
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become a reasonable alternative for an initial agent. In dogs and cats, the ideal therapeutic 
target is a reduction in the UPC to <1 without inappropriate worsening of renal function. 
Because this ideal target is not achieved in most animals, a reduction in UPC of 50% or 
greater is often the target. The degree to which worsening of renal function is tolerated will 
in part depend upon the stage of CKD the dog is in. Dogs with stage 1 and 2 CKD can have 
an increase in serum creatinine of up to 30% without modifying therapy. The goal in dogs 
with stage 3 CKD would be to maintain stable renal function, allowing only for a 10% 
increase in serum creatinine. If renal function deteriorates beyond these allowances, 
therapeutic adjustments may be indicated. Dogs with stage 4 CKD are generally intolerant 
of worsening of renal function and any deterioration may have clinical consequences. 
Whereas RAAS inhibitors can be used in this subset of patients, the initial starting doses 
and incremental dose increases should be very low and renal function should be monitored 
closely; therapeutic adjustments may be needed to maintain baseline renal function.  
If the target reduction in UPC is not achieved, the plasma potassium concentration is 
<6 and any changes in renal function fall within the tolerable limit, dosages may be 
increased every 4-6 weeks.  If the target reduction in UPC is not achieved with a maximal 
dosage an ACEi, the next step should be to add an ARB. Alternatively an ARB can be used as 
monotherapy in dogs who appear to be intolerant of an ACEi.   
Managing Hyperkalemia 
Hyperkalemia appears to be a common side effect of RAAS inhibition in dogs with  
kidney disease but is probably uncommon in cats. Pseudohyperkalemia, often associated 
with thrombocytosis, can also occur in dogs and needs to be ruled-out by measuring the 
potassium concentration in lithium heparin plasma before taking further action. Because of 
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the cardiotoxic effects of potassium, dogs or cats with true hyperkalemia of > 5.5 mEq/L 
should be monitored closely; therapy should be modified if serum potassium 
concentrations are >6 to 6.5 mEq/L. When plasma potassium concentrations are >6mEq/L, 
an ECG should be evaluated for cardiac conduction disturbances. True hyperkalemia can be 
managed by reducing the ACEi or ARB drug dosage, discontinuing spironolactone 
administration, or by feeding diets that are reduced in potassium (note that renal diets may 
be supplemented with potassium). The use of an intestinal potassium binder (e.g., 
kayexelate) has been limited in dogs. Rarely hyperkalemia would be severe enough to 
warrant hemodialysis. Potassium-reduced home-prepared diets that were formulated by a 
veterinary nutritionist have been shown to effectively correct hyperkalemia long-term in 
dogs with chronic kidney disease (Segev et al, 2010). 
 
Management of Hypertension  
 The kidney is one of the target organs for hypertensive damage and sustained 
hypertension may lead to an increased magnitude of proteinuria, rate of decline of renal 
function, frequency of uremic crises and mortality (Jepson et al, 2009, Finco et al, 2004; 
Brown et al, 2007). The goal of antihypertensive therapy is to reduce the blood pressure so 
that the risk of continued target organ damage is minimized (Table 4). Inhibitors of RAAS 
are generally only weak antihypertensive agents, leading to a reduction in blood pressure 
by only about 10-15%. Dogs and cats that have sustained systolic blood pressures ≥160 
mmHg while being administered a RAAS inhibitor have a moderate to high risk of future 
target organ damage and may need additional therapeutic consideration. In these animals, 
the first step is to increase the dose of the RAAS inhibitor. If the upper end of the dosage 
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range is being administered and the risk of target organ damage remains moderate to high, 
the next step is to add a calcium channel blocker. Amlodipine is usually used with a starting 
dose of 0.2-0.4 mg/kg q24 hours but can be incrementally increased to a total daily dose of 
0.75 mg/kg, which can be divided to q12h. There is evidence that amlodipine will activate 
the RAAS system; therefore it should not be used as monotherapy for the management of 
hypertension in dogs (Atkins et al, 2007). However in cats monotherapy may be more 
appropriate because giving multiple drugs is harder, amlodipine alone may bring the UPC 
down to <0.2 in hypertensive cats and amlodipine-induced increases in plasma renin 
activity are not associated with an increase in aldosterone in cats (Jepson et al, 2014).  
Systolic blood pressure should be monitored during therapy and maintained >120 
mmHg in treated dogs and cats. High salt intake should be avoided although salt restriction 
alone will not adequately reduce blood pressure.  
 
Diet 
In animal models of chronic kidney disease, the magnitude of proteinuria can be 
reduced by dietary modification – specifically by modifying the polyunsaturated fatty acid 
ratio and protein content (Brown et al, 2013). Dietary supplementation with n-3 
polyunsaturated fatty acids or feeding a diet that has a reduced n-6/n-3 ratio that is close 
to 5:1, as found in most commercially available renal diets is expected to alter the long term 
course of renal injury and reduce the magnitude of proteinuria. It is generally accepted that 
feeding a renal diet that is modified in protein content reduces intraglomerular pressure as 
well as the magnitude of proteinuria and the generation of uremic toxins. However, the 
magnitude of this reduction in proteinuria is small. Renal diet alone should not be expected 
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to adequately reduce proteinuria in most animals.  
 
Renal Biopsy 
Nearly 60% of dogs with glomerular proteinuria will have either immune-complex 
mediated glomerulonephritis or amyloidosis (Schneider et al, 2013), both of which may 
represent an aberrant or excessive immune or inflammatory response to an infectious, 
neoplastic or inflammatory condition. Cats rarely get glomerulonephritis but a percentage 
of these cats would also be expected to have developed this secondary to a systemic 
disease. Therefore, in dogs or cats with glomerular proteinuria it is indicated to pursue 
extended diagnostic testing, the extent of which might vary depending upon patient 
characteristics and potential exposure to regional infectious agents (Littman et al, 2013). It 
is possible that complete or partial resolution of proteinuria will follow successful 
treatment of any causative systemic diseases.  
Renal biopsy should be considered in animals with persistent glomerular range 
proteinuria that do not have any contraindications to renal biopsy and have not responded 
to standard therapy (Littman et al, 2013). Some of the more common contraindications to 
biopsy include chronic kidney disease with serum creatinine >5 mg/dL, uncontrolled 
hypertension, pyelonephritis, renal cystic disease, coagulopathy, hydronephrosis, and 
severe anemia. When biopsy samples are processed correctly, clinical decisions regarding 
the diagnosis, treatment, and prognosis can be made from the information obtained 
through renal biopsy in dogs. Experienced personnel should be involved with procuring, 
preparing and interpreting the renal biopsy that has been processed for light, electron, and 
immunofluorescence microscopy.  
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From a therapeutic standpoint, the primary purpose of the renal biopsy is to 
determine if immunosuppressive therapy is indicated or not. Finding electron-dense 
deposits in subendothelial, subepithelial, intramembranous, or mesangial locations of the 
glomerulus by EM or demonstrating positive and unequivocal immunofluorescent staining 
for immunoglobulins and/or complement in an immune-complex and antiglomerular 
basement membrane pattern of deposition in peripheral capillary loops or the mesangial 
compartment with IFM provides compelling evidence to initiate a trial of 
immunosuppressive therapy (Segev et al, 2013). Probable evidence of an 
immunopathogenesis can be documented by LM with one of the following: red granular 
staining of capillary walls with Masson’s trichrome, spikes along the GBM or holes within 
the GBM with Jones Methenamine sliver stain. These findings would be expected in just 
under 50% of dogs with glomerular disease (Schneider et al, 2013). When renal biopsy 
results are not available it becomes more difficult to make a decision about using 
immunosuppressive treatment because approximately 50% of dogs with glomerular 
disease would be expected not to have an immunopathogenesis of their disease. Consensus 
recommendations are to consider immunosuppressive drugs in the treatment of dogs with 
glomerular disease when the source of proteinuria is clearly glomerular in origin, the drugs 
are not otherwise contraindicated, the dog breed and age of disease onset are not 
suggestive of a familial nephropathy, amyloidosis has been deemed unlikely and the serum 
creatinine is >3.0 mg/dl or progressively increasing, or the serum albumin is <2.0 g/dl 
(Pressler et al, 2013). 
 
Immunosuppressive Agents 
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Empirical administration of immunosuppressive or anti-inflammatory therapy has 
been recommended for dogs that have no known contraindications for the specific drugs 
being considered and have severe, persistent, or progressive glomerular disease in which 
there is renal biopsy-supported evidence of immune-mediated pathogenesis (Segev et al, 
2013). Dogs with more severe disease or rate of progression should be treated more 
aggressively than those with more stable disease. Single agent or combination therapy for 
rapid onset of immunosuppression should be considered in dogs with high magnitude 
proteinuria with hypoalbuminemia, NS, or rapidly progressive azotemia (Segev et al, 2013). 
Mycophenolate, or cyclophosphamide, with or without short-term administration of 
glucocorticoids, has been suggested as the first choice. Glucocorticoids should be limited to 
short-term therapy because of the potential association with corticosteroid excess and 
proteinuria. Dogs with stable or more slowly progressive disease that have only partial or 
no response to standard therapy might be given drugs that have a either a rapid or a more 
delayed onset of drugs, such as mycophenolate, chlorambucil or cyclophosphamide. 
Cyclosporine has also been suggested as a first choice for stable or slowly progressive dogs. 
It is important to note that this is the only drug that has been studied prospectively in dogs 
with glomerular disease and was found to be of no benefit, although there were flaws in the 
design of that study (Vaden et al, 2995).  
All dogs treated with immunosuppressive therapy for their glomerular disease 
should be monitored closely. Treatment should be discontinued or adjusted if adverse drug 
effects develop. In the absence of adverse effects, 8-12 weeks of therapy should be 
provided before changing the course of treatment. If the therapeutic response is 
suboptimal at the end of 8-12 weeks, an alternate drug protocol should be considered. 
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However, if after 3-4 months a therapeutic response has not been achieved, consideration 
should be given to discontinuing immunosuppressive drug administration. If after this 
time, a response has been noted, the drug dose or schedule should be tapered to one that 
maintains the response without worsening of proteinuria, azotemia or clinical signs (Segev 
et al, 2013). 
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Table 1: International Renal Interest Society classification of proteinuria in dogs and cats 
with chronic kidney disease.  
Substage Cat* Dog 
Nonproteinuric (NP) <0.2 <0.2 
Borderline Proteinuric (BP) 0.2-0.4 0.2-0.5 
Proteinuric (P) >0.4 >0.5 
*Applies to normal female and neutered male cats; normal intact male cats may have a UPC 
as high as 0.6. 
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Table 2. Categorization of Potential Causes of Proteinuria in Dogs and Cats 
Category Mechanism Potential Causes 
Pre-renal Greater than normal delivery 
of low molecular weight 
plasma proteins to the 
normal glomerulus 
 Hemoglobinuria from intravascular 
hemolysis  
 Myoglobinuria from rhabdomyolysis   
 Immunoglobulin light chains from 
multiple myeloma or lymphoma 
Renal Abnormal renal handling of 
normal plasma proteins 
caused by one of the 
following subcategories: 
 
 Functional 
(Physiological) 
Altered renal physiology in 
response to transient 
stressor 
 Strenuous exercise 
 Fever 
 Seizure 
 Exposure to extreme heat or cold 
 
 Glomerular Altered permselectivity of 
the glomerular basement 
membrane 
 
 Any cause of glomerular injury or 
dysfunction (e.g., 
membranoproliferative 
glomerulonephritis, 
glomerulosclerosis, amyloidosis) 
 
 Tubular* Impaired tubular recovery of 
plasma proteins that are 
normally found in the 
glomerular filtrate 
 
 Any cause of renal tubular 
dysfunction (e.g., acute tubular 
necrosis, Fanconi syndrome)  
 Interstitial* Exudation of proteins from 
the interstitial space into the 
urinary space 
 Interstitial nephritis 
Post-renal Entry of protein into the 
urine in association with 
exudation of blood or serum 
into the lower urinary or 
genital tracts 
 Urinary tract infection 
 Urolithiasis 
 Transitional cell carcinoma 
 Vaginitis 
* Tubular and interstitial can be difficult to separate in a clinical setting and are often 
referred to as tubulointerstitial. 
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Table 3: Inhibitors of RAAS used in dogs and cats with chronic kidney disease 
Class Drug Initial Dose Escalating Dose Strategy 
Angiotensin 
converting 
enzyme 
inhibitors 
Benazapril 0.25-0.5 mg/kg 
PO q24 hr* 
Dog or cat 
Increase by 0.25-0.5 mg/kg to a 
maximum daily dose of 2 
mg/kg; can be given q12h 
 
 Enalapril 0.25-0.5 mg/kg 
PO q24 hr* 
Dog or cat 
Increase by 0.25-0.5 mg/kg to a 
maximum daily dose of 2 
mg/kg; can be given q12h 
 
 Lisinopril 0.25-0.5 mg/kg 
PO q24 hr* 
Dog or cat 
Increase by 0.25-0.5 mg/kg to a 
maximum daily dose of 2 
mg/kg; can be given q12h 
 
 Ramipril 0.125 mg/kg  
PO q24h 
Dog 
Increase by 0.125 mg/kg q24h 
to a maximum of 0.5 mg/kg 
q24h; usually given q24h 
 
 Imidapril 0.25 mg/kg  
PO q24h 
Dog 
Increase by 0.25 mg/kg q24h to 
a maximum of 2 mg/kg q24h; 
usually given q24h 
    
Angiotensin 
receptor 
blockers 
Telmisartan** 0.5-1.0 mg/kg 
PO q24h 
Dog 
Dog or cat 
Increase by 0.25-0.5 mg/kg to a 
maximum daily dose of 5 
mg/kg; usually given q24h 
    
 Losartan*** 0.25-0.5 mg/kg 
PO q24 hr 
Dog 
Increase by 0.25-0.5 mg/kg to a 
maximum daily dose of 2 
mg/kg; can be given q12h 
    
Aldosterone 
receptor 
blocker 
Spironolactone**** 0.5-2 mg/kg   
PO q12-24h 
Dog 
 
 
*Smaller starting doses should be used in animals with in stage 3 or 4 CKD or if there are 
concurrent medical problems that have the potential to lead to dehydration or reduced 
appetite.   
**Can be used a single agent or combined with an ACEi. 
***Concurrent administration of an ACEi is generally recommended. 
****Only recommended in dogs with glomerular disease that have increased serum or 
urine aldosterone concentrations and have failed or not tolerated an ACEi or ARB. 
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Table 4: Staging of blood pressure in dogs and cats according to the risk for future target 
organ damage.  
Blood Pressure Stage Systolic 
(mmHg)  
Diastolic 
(mmHg) 
APO – Risk none to minimal <150 <95 
AP1 – Low risk 150-159 95-99 
AP2 – Moderate risk 160-179 110-119 
AP# - High risk 180 120 
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Figure Legends 
Figure 1. The renin-angiotensin-aldosterone system and its inhibitors.  
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Figure 2. Making adjustments to RAAS inhibition therapy in dogs with renal proteinuria. 
 
